Timetable

RNS Number : 1761H

The MedicX Fund Limited

15 February 2010

 



THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, REPUBLIC OF IRELAND, REPUBLIC OF SOUTH AFRICA, NEW ZEALAND OR JAPAN

For Immediate Release

15 February 2010

MedicX Fund Limited

("MedicX Fund", the "Fund" or the "Company")

Timetable

Further to the announcement made by the Fund earlier today regarding the publication of a prospectus in connection with the proposed Placing, Open Offer and Offer for Subscription, the Record Date for entitlements under the Open Offer is 12 February 2010.  

Key dates for the timetable are as follows:

Expected Timetable

Event	Time and Date (2010)
Record Date	Close of business on 12 February
Ex entitlement date for the Open Offer Open Offer Entitlements and Excess CREST Open Offer Entitlements credited to stock accounts of Qualifying CREST Shareholders into CREST	8 a.m. on 16 February
Last time and date for receipt of completed Application Forms and payment in full under the Open Offer or Settlement of the relevant CREST Instruction	11 a.m. on 2 March
Last time and date for receipt of Forms of Proxy	2.30 p.m. on 2 March
General Meeting	2.30 p.m. on 4 March
Last time and date for receipt of completed Application Forms and payment in full under the Offer for Subscription	1 p.m. on 5 March
Last time and date for receipt of Placing commitments	Noon on 8 March
Admission and commencement of dealings in New Ordinary Shares	8 a.m. on 12 March
CREST Stock Account to be credited	12 March
Certificates in respect of New Ordinary Shares in certificated form	Week commencing 15 March

Each of the times and dates in the above timetable is subject to change, in which event details of the new times and/or dates will be notified to the UK Listing Authority and the London Stock Exchange and, where appropriate, Shareholders. References to times in the Prospectus are to GMT/BST.

Defined terms in this announcement (except where the context otherwise requires) bear the same meaning as those terms when used in the Prospectus.

Further information on the Company can be found on the Company's website - www.medicxfund.com

For further information please contact:

MedicX Fund                                                                            [phone]

David Staples, Chairman

MedicX Group                                                                          [phone]

Keith Maddin, Chairman

Mike Adams, Chief Executive Officer

Mark Osmond, Chief Financial Officer

Collins Stewart                                                                        [phone]

Andrew Zychowski (Corporate)

Lucy Lewis (Corporate)

Dominic Waters (Sales)

Neil Brierley (Sales)

Will Barnett (Sales)       

Buchanan Communications                                                     [phone]

Charles Ryland

Lisa Baderoon

Miranda Higham

Important Information

This announcement and the information contained herein is restricted and is not for publication, release or distribution in whole or in part in the United States, Japan, Canada, Australia, Republic of South Africa, New Zealand or the Republic of Ireland.

This announcement does not constitute or form part of any offer or invitation to sell, or any solicitation of any offer to purchase, any securities of the Company and any purchase of securities of the Company pursuant to any equity issue undertaken by the Company should only be made on the basis of the information contained in the final prospectus published by the Company and any supplement or amendment thereto (the "Prospectus").  Copies of the Prospectus may, subject to any applicable law, be obtained at no cost at the registered office of the Company, Collins Stewart or from the Document Viewing Facility, UK Listing Authority, The Financial Services Authority, 25 North Colonnade, Canary Wharf, London E14 5HS. The Prospectus will supersede all information provided before the date of the Prospectus and any investment decision must be made only on the basis of the information contained therein.

Certain statements contained in this announcement may be forward-looking statements.  By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements.  These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. Neither Collins Stewart or the Company undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  A prospective investor should not place undue reliance on forward-looking statements, which speak only as of the date of this announcement.

The contents of this announcement have been prepared by and are the sole responsibility of the Company.

Collins Stewart Europe Limited, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting as sponsor to MedicX Fund Limited and is acting for no-one else in connection with the Issue and the contents of this announcement, and will not be responsible to anyone other than the Company for providing the protections afforded to clients of Collins Stewart Europe Limited nor for providing advice in connection with the Issue and the contents of this announcement or any other matter referred to herein. Collins Stewart Europe Limited is not responsible for the contents of this announcement. This does not exclude or limit any responsibilities which Collins Stewart Europe Limited may have under the Financial Services and Markets Act 2000 or the regulatory regime established thereunder.

 

END

 

 

MSCGGUPCPUPUGQA